Cargando…

Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs)

Small-interfering ribonucleic acids (siRNAs) with N-acetylgalactosamine (GalNAc) conjugation for improved liver uptake represent an emerging class of drugs that modulate liver-expressed therapeutic targets. The pharmacokinetics of GalNAc-siRNAs are characterized by a rapid distribution from plasma t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sten, Sebastian, Cardilin, Tim, Antonsson, Madeleine, Gennemark, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Leading Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684612/ https://www.ncbi.nlm.nih.gov/pubmed/37824025 http://dx.doi.org/10.1007/s40262-023-01314-7

Ejemplares similares

Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs
por: Boianelli, Alessandro, et al.
Publicado: (2022)

Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates
por: Brown, Christopher R, et al.
Publicado: (2020)

Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates
por: Nair, Jayaprakash K., et al.
Publicado: (2017)

Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates
por: Foster, Donald J., et al.
Publicado: (2018)

GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
por: Thangamani, Lokesh, et al.
Publicado: (2021)

Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs
por: Agarwal, Saket, et al.
Publicado: (2021)

Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
por: Janas, Maja M., et al.
Publicado: (2018)

Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
por: Janas, Maja M, et al.
Publicado: (2019)

Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression
por: Willoughby, Jennifer L.S., et al.
Publicado: (2018)

From bench to bedside: Improving the clinical safety of GalNAc–siRNA conjugates using seed-pairing destabilization
por: Schlegel, Mark K, et al.
Publicado: (2022)

Combination treatment of mannose and GalNAc conjugated small interfering RNA protects against lethal Marburg virus infection
por: Ye, Xin, et al.
Publicado: (2023)

Two Birds with One Stone: A Novel Dithiomaleimide-Based GalNAc-siRNA Conjugate Enabling Good siRNA Delivery and Traceability
por: Kong, Sudong, et al.
Publicado: (2023)

RAB18 is a key regulator of GalNAc-conjugated siRNA-induced silencing in Hep3B cells
por: Lu, Jiamiao, et al.
Publicado: (2022)

The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
por: Janas, Maja M., et al.
Publicado: (2018)

Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
por: Kim, Youngsoo, et al.
Publicado: (2019)

Synthesis of 5′-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies
por: Cedillo, Isaiah, et al.
Publicado: (2017)

The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates
por: Zhang, Lei, et al.
Publicado: (2022)

Overexpression of GalNAc-transferase GalNAc-T3 Promotes Pancreatic Cancer Cell Growth
por: Taniuchi, Keisuke, et al.
Publicado: (2011)

GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
por: Sewing, Sabine, et al.
Publicado: (2018)

Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis
por: Sutherland, Jessica E., et al.
Publicado: (2020)

Assessment of the Drug Interaction Potential of Unconjugated and GalNAc(3)-Conjugated 2′-MOE-ASOs
por: Shemesh, Colby S., et al.
Publicado: (2017)

SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1
por: Altamura, Sandro, et al.
Publicado: (2019)

Targeting ANGPTL3 by GalNAc-conjugated siRNA ANGsiR10 lowers blood lipids with long-lasting and potent efficacy in mice and monkeys
por: Wang, Jue, et al.
Publicado: (2022)

Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice
por: Yu, Rosie Z, et al.
Publicado: (2016)

Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021)

Chimeric siRNAs with chemically modified pentofuranose and hexopyranose nucleotides: altritol-nucleotide (ANA) containing GalNAc–siRNA conjugates: in vitro and in vivo RNAi activity and resistance to 5′-exonuclease
por: Kumar, Pawan, et al.
Publicado: (2020)

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region
por: Han, Kelong, et al.
Publicado: (2022)

Expression of alpha-GalNAc glycoproteins by breast cancers.
por: Brooks, S. A., et al.
Publicado: (1995)

The GalNAc-T Activation (GALA) Pathway: Drivers and markers
por: Chia, Joanne, et al.
Publicado: (2019)

Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor
por: Scharner, Juergen, et al.
Publicado: (2019)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

The Gal/GalNac lectin as a possible acetylcholine receptor in Entamoeba histolytica
por: Pacheco-Sánchez, Marisol, et al.
Publicado: (2023)

Molecular Recognition of GalNAc in Mucin-Type O-Glycosylation
por: Sanz-Martinez, Ignacio, et al.
Publicado: (2023)

Overcoming GNA/RNA base-pairing limitations using isonucleotides improves the pharmacodynamic activity of ESC+ GalNAc-siRNAs
por: Schlegel, Mark K, et al.
Publicado: (2021)

Structures of Complexes of a Metal-independent Glycosyltransferase GT6 from Bacteroides ovatus with UDP-N-Acetylgalactosamine (UDP-GalNAc) and Its Hydrolysis Products
por: Pham, Tram T. K., et al.
Publicado: (2014)

Evidence of Gene Conversion in Genes Encoding the Gal/GalNac Lectin Complex of Entamoeba
por: Weedall, Gareth D., et al.
Publicado: (2011)

Targeting Angiotensinogen With N-Acetylgalactosamine–Conjugated Small Interfering RNA to Reduce Blood Pressure
por: Ye, Dien, et al.
Publicado: (2023)

Role of GalNAc4S-6ST in Astrocytic Tumor Progression
por: Kobayashi, Tatsuya, et al.
Publicado: (2013)

Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells
por: Tsuchida, Akiko, et al.
Publicado: (2018)

Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
por: Huang, Yuanyu
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9m9l9adfth110ti884l0r4plu2